PMC7859638_01
Thyroid uptake patterns in the patient before and after 177Lu-DOTATATE therapy. (A) A whole body (maximum intensity projection) view on the diagnostic 68Ga-DOTATATE scan demonstrating multiple paragangliomas as well as a diffuse uptake in the thyroid gland with a maximum standardized uptake value (SUVmax) of 14.3. (B-D) Axial slices at the thyroid level: (B) Positron emission tomography (PET) scan only. (C) Computed tomography (CT) scan only. (D) Fused PET and CT images. Images (B, D) demonstrate diffuse uptake in the thyroid gland. (E, F) The 24-h post-treatment whole body single-photon emission computed tomography (SPECT) scans demonstrating diffuse uptake of 177Lu-DOTATATE in the thyroid gland (E) After the first cycle of therapy, and (F) after the second cycle of therapy.
fendo-11-587065-g001.jpg
PMC7859638_01_fendo-11-587065-g001.jpg
f1
A diagnostic gallium 68 (68Ga)-DOTATATE positron emission tomography-computed tomography (PET/CT) that was performed prior to the initiation of 177Lu-DOTATATE therapy revealed diffuse increase in the uptake in the entire thyroid gland, with a maximum standardized uptake value (SUVmax) of 14.3 ( Figures 1A-D ). A post-treatment single-photon emission computed tomography (SPECT) scans revealed diffuse uptake of 177Lu-DOTATATE in the thyroid gland ( Figures 1E, F ).